肿瘤细胞治疗研究
FRONTIER PAPERS
PD-L1(+) exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy.
PD-L1+外泌体可能作为 MM 疾病侵袭性和 CAR-T 治疗结局的生物标志物。通过损害 CD8+ T 细胞功能并促进终末耗竭，它们可能促进免疫抵抗。联合外泌体释放通路阻断与 PD-1 阻断作为增强 CAR-T 疗效的策略值得进一步研究。
Low-dose docetaxel reprograms CAR T cells for enhanced solid tumor immunity.
这些发现描述了一种非遗传药理学预激活策略，具有潜在的可扩展性并与现有生产工艺兼容。该方法在临床前模型中展示了增强的 CAR-T 细胞对抗实体瘤屏障的性能，突显了化疗-免疫治疗协同作用的潜力。
Heparanase-Loaded CAR T Extracellular Vesicles Remodel the Colorectal Tumour Microenvironment and Boost T Cell Antitumor Immunity.
A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.
B7-H3 (CD276) in exosome biogenesis and the tumor microenvironment: a new therapeutic nexus.
In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers.
Mitochondria transfer: intercellular communication and tumor microenvironment dynamics.
Biomarker-empowered precision navigation of CAR-T cell therapy.
Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer.
Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
